Articles by Rita Peters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rita Peters

Trust in the Pill Bottle

The Ranbaxy settlement provides a cautionary tale for patients, FDA, and drug manufacturers.
Jun 2, 2013

Ranbaxy's $500 million settlement for producing adulterated drugs and fradulent data provides a cautionary tale for patients, FDA, and drug manufacturers.

Pathway to Publication

Wanted: Article contributions on drug and process development topics.
May 2, 2013

Wanted: Article contributions on drug and process development topics.

FDA Will Not Approve Generics to Original OxyContin

Apr 17, 2013

The FDA approved updated labeling for Purdue Pharma L.P.?s reformulated OxyContin tablets, but also determined that it will not approve generic versions of the original OxyContin.

More than 900 Biologics in Development

Mar 11, 2013

America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report.

European Patent Filings Up, But Pharma Stays Flat

Mar 7, 2013

While the number of patent filings at the European Patent Office in 2012 increased by 5.2% over 2011, pharmaceutical-based patents remained flat, and biotechnology patents dropped slightly.

Russian Lab Achieves ISO Accreditation

Mar 5, 2013

The Rostov-on-Don Medicines Quality Control Laboratory is the first official medicines control laboratory in Russia to have achieved internationally recognized ISO accreditation.

Catching Up

QbD paradigm advances process understanding in development and manufacturing.
Mar 2, 2013

QbD paradigm advances process understanding in development and manufacturing.

Capsugel Acquires Encap Drug Delivery

Mar 1, 2013

Capsugel’s acquisition of Encap Drug Delivery expands its lipid expertise and adds an FDA-inspected commercial manufacturing facility.

Sequestration Threatens Life Sciences, Drug Development

Mar 1, 2013

Mandatory cuts threaten to slow research and patient access to new therapies, Burrill & Company says.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here